See more : Grand Process Technology Corporation (3131.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Ningxia Western Venture Industrial Co.,Ltd. (000557.SZ) Income Statement Analysis – Financial Results
- Hut 8 Mining Corp. (HUT) Income Statement Analysis – Financial Results
- Henan Jinyuan Hydrogenated Chemicals Co., Ltd. (2502.HK) Income Statement Analysis – Financial Results
- Baltic International USA, Inc. (BISA) Income Statement Analysis – Financial Results
- PharmaTher Holdings Ltd. (PHRRF) Income Statement Analysis – Financial Results
Thermo Fisher Scientific Inc. (TMO)
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B | 13.09B | 12.51B | 11.73B | 10.79B | 10.11B | 10.50B | 9.75B | 3.79B | 2.63B | 2.21B | 2.10B | 2.09B | 2.19B | 2.28B | 2.47B | 3.87B | 3.56B | 2.93B | 2.21B | 1.59B | 1.25B | 949.00M | 805.50M | 708.00M | 579.00M | 500.60M | 383.40M | 331.60M | 265.70M |
| Cost of Revenue | 25.74B | 25.42B | 18.98B | 15.71B | 13.72B | 12.99B | 10.96B | 9.46B | 8.78B | 8.97B | 7.34B | 6.99B | 6.74B | 6.22B | 5.96B | 6.29B | 5.94B | 2.22B | 1.44B | 1.19B | 1.15B | 1.16B | 1.23B | 1.26B | 1.26B | 2.02B | 1.84B | 1.54B | 1.12B | 866.30M | 713.10M | 579.80M | 510.20M | 443.00M | 384.10M | 325.70M | 248.70M | 219.30M | 174.30M |
| Gross Profit | 17.11B | 19.50B | 20.23B | 16.51B | 11.83B | 11.36B | 9.96B | 8.82B | 8.18B | 7.92B | 5.75B | 5.52B | 4.99B | 4.57B | 4.15B | 4.21B | 3.80B | 1.57B | 1.19B | 1.01B | 948.02M | 927.38M | 958.62M | 1.02B | 1.21B | 1.84B | 1.72B | 1.39B | 1.08B | 719.00M | 536.60M | 369.20M | 295.30M | 265.00M | 194.90M | 174.90M | 134.70M | 112.30M | 91.40M |
| Gross Profit Ratio | 39.93% | 43.42% | 51.60% | 51.23% | 46.30% | 46.65% | 47.60% | 48.24% | 48.23% | 46.89% | 43.93% | 44.10% | 42.54% | 42.39% | 41.04% | 40.07% | 39.03% | 41.36% | 45.38% | 45.99% | 45.21% | 44.45% | 43.81% | 44.81% | 48.81% | 47.65% | 48.36% | 47.40% | 49.05% | 45.35% | 42.94% | 38.90% | 36.66% | 37.43% | 33.66% | 34.94% | 35.13% | 33.87% | 34.40% |
| Research & Development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 888.00M | 754.80M | 692.30M | 691.10M | 395.50M | 376.40M | 340.60M | 287.20M | 246.10M | 249.10M | 238.70M | 170.18M | 152.78M | 134.68M | 146.39M | 155.12M | 171.61M | 176.76M | 171.10M | 367.30M | 337.30M | 0.00 | 269.60M | 103.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.45B | 7.13B | 6.84B | 5.76B | 4.93B | 4.82B | 4.41B | 4.04B | 3.72B | 3.99B | 2.91B | 2.83B | 2.65B | 2.39B | 2.20B | 2.69B | 2.55B | 1.11B | 761.79M | 626.46M | 568.14M | 564.66M | 620.10M | 646.92M | 673.00M | 937.60M | 840.70M | 990.70M | 480.80M | 373.20M | 370.60M | 271.70M | 233.60M | 210.60M | 164.40M | 144.60M | 117.10M | 91.60M | 78.70M |
| Other Expenses | 536.00M | 2.40B | 1.76B | 1.67B | 1.71B | 9.00M | -28.00M | -4.10M | -15.50M | 16.40M | -56.00M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| Operating Expenses | 10.24B | 10.99B | 10.01B | 8.61B | 7.65B | 7.53B | 6.89B | 6.18B | 5.73B | 6.01B | 4.06B | 3.95B | 3.64B | 3.25B | 3.04B | 2.94B | 2.79B | 1.28B | 914.56M | 761.14M | 714.53M | 719.78M | 791.72M | 823.68M | 957.70M | 1.47B | 1.31B | 1.11B | 835.40M | 539.20M | 413.00M | 300.90M | 257.00M | 229.40M | 177.10M | 155.70M | 127.20M | 100.00M | 86.50M |
| Cost & Expenses | 36.00B | 36.41B | 28.99B | 24.33B | 21.36B | 20.53B | 17.85B | 15.64B | 14.51B | 14.98B | 11.40B | 10.95B | 10.38B | 9.46B | 9.00B | 9.23B | 8.73B | 3.50B | 2.35B | 1.95B | 1.86B | 1.88B | 2.02B | 2.08B | 2.22B | 3.49B | 3.15B | 2.65B | 1.96B | 1.41B | 1.13B | 880.70M | 767.20M | 672.40M | 561.20M | 481.40M | 375.90M | 319.30M | 260.80M |
| Interest Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M | 137.00M | 81.00M | 48.40M | 30.60M | 47.70M | 28.00M | 25.20M | 26.90M | 12.50M | 16.10M | 51.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.60M | 414.90M | 479.90M | 262.10M | 241.60M | 175.30M | 84.70M | 118.10M | 151.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 863.50M | 770.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 58.55M | 56.38M | 98.52M | 97.49M | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| EBITDA | 11.20B | 11.94B | 12.96B | 10.19B | 6.46B | 6.20B | 5.25B | 4.25B | 4.04B | 4.25B | 2.58B | 2.49B | 2.18B | 1.91B | 1.83B | 2.07B | 1.78B | 502.07M | 435.89M | 336.34M | 279.30M | 193.08M | 265.43M | 295.65M | 362.20M | 353.40M | 371.60M | 399.40M | 332.30M | 242.10M | 166.00M | 97.50M | 61.70M | 54.40M | 30.50M | 30.30M | 17.60M | 20.70M | 12.70M |
| EBITDA Ratio | 26.12% | 26.84% | 31.03% | 31.67% | 25.88% | 25.64% | 24.62% | 24.30% | 24.49% | 21.63% | 20.31% | 20.60% | 19.07% | 19.54% | 18.92% | 19.95% | 18.65% | 15.11% | 14.55% | 14.22% | 14.63% | 9.25% | 16.53% | 13.55% | 23.20% | 13.51% | 12.97% | 10.53% | 9.21% | 10.02% | 12.68% | 4.16% | 0.30% | 2.53% | -0.14% | 1.96% | -1.85% | 3.44% | 0.45% |
| Operating Income | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.97B | 2.45B | 2.34B | 2.50B | 1.61B | 1.48B | 1.25B | 1.26B | 1.05B | 1.23B | 974.40M | 241.96M | 263.49M | 237.51M | 184.77M | 155.45M | 34.20M | 198.16M | 248.60M | 375.80M | 407.00M | 284.20M | 247.30M | 179.80M | 123.60M | 68.30M | 38.30M | 35.60M | 17.80M | 19.20M | 7.50M | 12.30M | 4.90M |
| Operating Income Ratio | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.19% | 13.40% | 13.77% | 14.82% | 12.30% | 11.85% | 10.62% | 11.72% | 10.38% | 11.71% | 10.00% | 6.38% | 10.01% | 10.77% | 8.81% | 7.45% | 1.56% | 8.69% | 10.06% | 9.72% | 11.44% | 9.69% | 11.20% | 11.34% | 9.89% | 7.20% | 4.75% | 5.03% | 3.07% | 3.84% | 1.96% | 3.71% | 1.84% |
| Total Other Income/Expenses | -561.00M | -558.00M | -1.19B | -567.00M | -524.00M | -521.00M | -531.00M | -434.10M | -399.60M | -415.80M | -290.10M | -212.70M | -112.40M | -100.30M | -121.80M | -79.80M | -93.10M | -32.59M | -7.88M | 4.78M | 35.25M | 131.50M | 42.32M | -23.90M | -230.10M | -28.30M | -100.30M | 17.40M | -8.30M | -7.20M | -13.60M | 19.80M | 33.70M | 15.40M | 16.40M | 8.20M | 15.20M | 4.90M | 6.90M |
| Income Before Tax | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B | 3.26B | 2.43B | 2.02B | 1.94B | 2.09B | 1.32B | 1.27B | 1.13B | 1.16B | 927.10M | 1.15B | 881.30M | 209.37M | 285.90M | 259.22M | 218.63M | 287.99M | 76.52M | 174.26M | 18.50M | 347.50M | 414.00M | 301.60M | 239.00M | 172.60M | 110.00M | 88.10M | 72.00M | 51.00M | 34.20M | 27.40M | 22.70M | 17.20M | 11.80M |
| Income Before Tax Ratio | 14.70% | 17.44% | 22.55% | 22.43% | 15.93% | 13.39% | 11.61% | 11.08% | 11.41% | 12.36% | 10.08% | 10.15% | 9.61% | 10.79% | 9.17% | 10.95% | 9.04% | 5.52% | 10.86% | 11.75% | 10.43% | 13.80% | 3.50% | 7.64% | 0.75% | 8.98% | 11.63% | 10.28% | 10.83% | 10.89% | 8.80% | 9.28% | 8.94% | 7.20% | 5.91% | 5.47% | 5.92% | 5.19% | 4.44% |
| Income Tax Expense | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.40M | -43.90M | 191.70M | 40.40M | 11.00M | 107.00M | 131.50M | 75.80M | 160.90M | 101.70M | 43.05M | 87.60M | 40.85M | 45.94M | 92.99M | 26.93M | 112.22M | 33.10M | 170.70M | 174.70M | 110.80M | 98.90M | 69.20M | 33.40M | 27.50M | 24.90M | 17.10M | 9.60M | 7.30M | 4.60M | 2.90M | 2.20M |
| Net Income | 6.00B | 6.95B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B | 1.27B | 1.18B | 1.33B | 1.04B | 850.30M | 994.20M | 761.10M | 168.94M | 223.22M | 361.84M | 200.01M | 309.73M | -781.00K | -36.11M | -174.60M | 181.90M | 239.30M | 190.80M | 140.10M | 103.40M | 76.60M | 59.20M | 47.10M | 33.90M | 24.60M | 20.10M | 18.10M | 14.30M | 9.60M |
| Net Income Ratio | 13.99% | 15.47% | 19.70% | 19.79% | 14.47% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.34% | 9.60% | 8.41% | 9.47% | 7.81% | 4.46% | 8.48% | 16.40% | 9.54% | 14.85% | -0.04% | -1.58% | -7.07% | 4.70% | 6.73% | 6.51% | 6.35% | 6.52% | 6.13% | 6.24% | 5.85% | 4.79% | 4.25% | 4.02% | 4.72% | 4.31% | 3.61% |
| EPS | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 | 3.53 | 3.24 | 3.49 | 2.57 | 2.06 | 2.34 | 1.81 | 0.86 | 1.38 | 2.22 | 1.23 | 1.84 | 0.00 | -0.22 | -1.11 | 1.12 | 1.57 | 1.35 | 1.11 | 0.93 | 0.33 | 0.18 | 0.17 | 0.14 | 0.11 | 0.10 | 0.09 | 0.07 | 0.04 |
| EPS Diluted | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.72 | 0.84 | 1.36 | 2.17 | 1.20 | 1.73 | 0.00 | -0.22 | -1.10 | 1.08 | 1.41 | 1.22 | 0.99 | 0.82 | 0.29 | 0.17 | 0.16 | 0.13 | 0.10 | 0.09 | 0.09 | 0.07 | 0.04 |
| Weighted Avg Shares Out | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 394.80M | 398.70M | 398.20M | 360.30M | 363.80M | 380.80M | 403.30M | 412.40M | 418.20M | 421.50M | 196.10M | 161.59M | 163.13M | 162.71M | 168.33M | 181.59M | 164.14M | 157.99M | 162.41M | 152.48M | 141.53M | 125.48M | 110.80M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
| Weighted Avg Shares Out (Dil) | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.40M | 401.90M | 402.30M | 365.80M | 366.60M | 384.80M | 409.40M | 423.03M | 434.70M | 443.70M | 203.70M | 165.33M | 167.64M | 170.73M | 179.03M | 185.02M | 164.14M | 158.22M | 168.43M | 169.79M | 175.70M | 158.10M | 145.53M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Thermo Fisher Scientific Showcases Expanded Biopharma Services, Capabilities and Innovations at CPHI Milan 2024
MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024, Oct. 8-10, in Milan, Italy. Leaders...
Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Thermo Fisher has outperformed the market with a 420%+ return over the past decade, but its current valuation is high. The company's recent results show mixed performance, with slight revenue decline, but improved earnings-per-share and raised 2024 guidance. Despite strong...
Exclusive: Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential
Stephens initiated coverage on Thermo Fisher Scientific TMO and cited the company as an industry leader in the broader life science tools/services/ diagnostics industry, with fiscal year 2023 sales of almost $42.9 billion.
Calls of the Day: General Motors, GE Healthcare, Thermo Fisher, HealthEquity, Carmax and SharkNinja
The Investment Committee debate the latest Calls Of The Day and Jim Lebenthal responds to Sarat Sethi selling out of General Motors
TMO Stock Gains From Innovation Amid Macroeconomic Issues
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. today launched the Thermo Scientific™ iCAP™ MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS). The launch includes a new single quadrupole Thermo Scientific iCAP MSX ICP-MS and...
Source: https://incomestatements.info
Category: Stock Reports